Please assess the completion status of the following clinical trial:

Trial Title: Geodon for the Treatment of Refractory Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults 18-65 years of age~* primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria~* minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline~* minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline~* written informed consent~* negative serum pregnancy test for women of childbearing potential~* normal EKG~Exclusion Criteria:~* current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition~* any current primary anxiety disorder other than SAD~* current primary depression~* history of substance abuse or dependence within the last 3 months~* suicide risk or serious suicide attempt within the last year~* clinically significant medical condition or laboratory or EKG abnormality~* women of childbearing potential who are unwilling to practice an acceptable method of contraception~* patients needing concurrent use of psychotropic medications~* history of hypersensitivity to sertraline or ziprasidone~* recent (less than 2 months) initiation of psychotherapy for SAD~* history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic~* patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open Label Treatment (Type: OTHER): 8 weeks of open label treatment with sertraline
- Randomization Ziprasidone (Type: OTHER): 8 weeks of treatment with sertraline augmented with ziprasidone
- Randomization Placebo (Type: OTHER): 8 weeks of treatment with sertraline augmented by placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).